Oncologychemoradiotherapyimmune checkpoint inhibitors
Dual Immune Checkpoint Blockade with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Insights from the CHINOREC Trial
By MedXY|Oct 4, 2025
The CHINOREC phase 2 trial demonstrates that adding ipilimumab and nivolumab to standard neoadjuvant chemoradiotherapy in rectal cancer is safe and feasible, showing promising clinical activity but no significant improvement in complete res
